Table 2. Patient disposition after... | American Society of Hematology

Table 2.

Patient disposition after median 21 months of follow-up

Patient disposition	n
Ongoing asciminib	82
80 mg once a day/40 mg twice daily	75
<80 mg once a day/40 mg twice daily	6
In combination with dasatinib	1
Registered but never started treatment	1
Discontinued asciminib	18
Adverse events	6
Failure to achieve EMR with intolerance for combination therapy³	2
Loss of response	4
Progression to AP/BC	1
Lost to follow-up/withdrawn consent	5

Patient disposition	n
Ongoing asciminib	82
80 mg once a day/40 mg twice daily	75
<80 mg once a day/40 mg twice daily	6
In combination with dasatinib	1
Registered but never started treatment	1
Discontinued asciminib	18
Adverse events	6
Failure to achieve EMR with intolerance for combination therapy³	2
Loss of response	4
Progression to AP/BC	1
Lost to follow-up/withdrawn consent	5

AP, accelerated phase; BC, blast crisis.